Compare RACE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RACE | TAK |
|---|---|---|
| Founded | 1947 | 1781 |
| Country | Italy | Japan |
| Employees | N/A | 47455 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.9B | 52.4B |
| IPO Year | 2015 | N/A |
| Metric | RACE | TAK |
|---|---|---|
| Price | $344.10 | $16.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $477.86 | N/A |
| AVG Volume (30 Days) | 518.6K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | 1.26% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | $0.16 |
| Revenue Next Year | $7.51 | $1.22 |
| P/E Ratio | ★ $34.59 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $312.51 | $12.99 |
| 52 Week High | $519.10 | $18.90 |
| Indicator | RACE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 36.05 |
| Support Level | $325.30 | $16.24 |
| Resistance Level | $380.68 | $16.48 |
| Average True Range (ATR) | 6.96 | 0.23 |
| MACD | 0.87 | 0.05 |
| Stochastic Oscillator | 99.48 | 36.70 |
Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2025, the company sold 13,640 vehicles at an average price over EUR 520,000 with more than 80% of its vehicles being sold to existing Ferrari clients. Eighty-four percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2025, the Europe, Middle East, and Africa region accounted for 49% of revenue, the Americas was 32%, mainland China, Hong Kong, and Taiwan was 7%, and the rest of Asia was 12%.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.